AU2010289746B2 - Novel forms of a multicyclic compound - Google Patents

Novel forms of a multicyclic compound Download PDF

Info

Publication number
AU2010289746B2
AU2010289746B2 AU2010289746A AU2010289746A AU2010289746B2 AU 2010289746 B2 AU2010289746 B2 AU 2010289746B2 AU 2010289746 A AU2010289746 A AU 2010289746A AU 2010289746 A AU2010289746 A AU 2010289746A AU 2010289746 B2 AU2010289746 B2 AU 2010289746B2
Authority
AU
Australia
Prior art keywords
compound
xrpd
crystalline form
crystalline
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010289746A
Other languages
English (en)
Other versions
AU2010289746A1 (en
Inventor
Stephen Bierlmaier
Michael Christie
Laurent Courvoisier
R. Scott Field
R. Curtis Haltiwanger
Linli He
Martin J. Jacobs
Michael Kress
Robert E. Mckean
Dale R. Mowrey
Joseph Petraitis
Mehran Yazdanian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43033463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010289746(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of AU2010289746A1 publication Critical patent/AU2010289746A1/en
Application granted granted Critical
Publication of AU2010289746B2 publication Critical patent/AU2010289746B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
AU2010289746A 2009-08-26 2010-08-25 Novel forms of a multicyclic compound Ceased AU2010289746B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23718009P 2009-08-26 2009-08-26
US61/237,180 2009-08-26
PCT/US2010/046671 WO2011028580A1 (en) 2009-08-26 2010-08-25 Novel forms of a multicyclic compound

Publications (2)

Publication Number Publication Date
AU2010289746A1 AU2010289746A1 (en) 2012-04-12
AU2010289746B2 true AU2010289746B2 (en) 2016-07-07

Family

ID=43033463

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010289746A Ceased AU2010289746B2 (en) 2009-08-26 2010-08-25 Novel forms of a multicyclic compound

Country Status (19)

Country Link
US (1) US8633314B2 (enExample)
EP (1) EP2470540B1 (enExample)
JP (3) JP2013503173A (enExample)
KR (1) KR20120092100A (enExample)
CN (1) CN102482282A (enExample)
AU (1) AU2010289746B2 (enExample)
BR (1) BR112012004053A2 (enExample)
CA (1) CA2772328C (enExample)
CL (1) CL2012000478A1 (enExample)
DK (1) DK2470540T3 (enExample)
EA (1) EA020756B1 (enExample)
ES (1) ES2572652T3 (enExample)
IL (1) IL218132B (enExample)
MX (1) MX2012002456A (enExample)
MY (1) MY156873A (enExample)
NZ (1) NZ598883A (enExample)
SG (1) SG178852A1 (enExample)
UA (1) UA110604C2 (enExample)
WO (1) WO2011028580A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク． 多環系化合物の新規形態
CA2967828A1 (en) 2014-11-26 2016-06-02 Cephalon, Inc. Crystalline forms of parp inhibitors
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063644A1 (en) * 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
CN101316592A (zh) * 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク． 多環系化合物の新規形態

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063644A1 (en) * 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent

Also Published As

Publication number Publication date
CL2012000478A1 (es) 2012-11-05
EP2470540A1 (en) 2012-07-04
JP2018035158A (ja) 2018-03-08
MX2012002456A (es) 2012-05-08
CA2772328A1 (en) 2011-03-10
EA020756B1 (ru) 2015-01-30
EA201270315A1 (ru) 2012-08-30
JP2016014029A (ja) 2016-01-28
WO2011028580A1 (en) 2011-03-10
MY156873A (en) 2016-04-15
KR20120092100A (ko) 2012-08-20
NZ598883A (en) 2014-09-26
BR112012004053A2 (pt) 2020-12-08
EP2470540B1 (en) 2016-04-20
AU2010289746A1 (en) 2012-04-12
CA2772328C (en) 2017-06-20
ES2572652T3 (es) 2016-06-01
HK1171750A1 (zh) 2013-04-05
CN102482282A (zh) 2012-05-30
US8633314B2 (en) 2014-01-21
UA110604C2 (uk) 2016-01-25
JP2013503173A (ja) 2013-01-31
SG178852A1 (en) 2012-04-27
DK2470540T3 (en) 2016-08-01
US20120214998A1 (en) 2012-08-23
IL218132A0 (en) 2012-06-28
IL218132B (en) 2018-02-28

Similar Documents

Publication Publication Date Title
US8633314B2 (en) Forms of a multicyclic compound
US11168057B2 (en) Polymorphs and co-crystals of roxadustat
KR102442536B1 (ko) 리나글립틴 결정형 및 이의 제조방법
CA3022250A1 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
WO2012066565A2 (en) Asenapine maleate amorphous and crystalline form and process for preparation thereof
TW202300147A (zh) 吡啶氮氧化合物晶型及其應用
PT2729470T (pt) (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-di-hidro-3'h-espiro[ciclo-hexano-1,1'-pirano[3,4,b]indol]-4-amina cristalina
KR20130038258A (ko) 삭사글립틴 중간체, 삭사글립틴 다형 및 이들의 제조 방법
WO2010070677A2 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
WO2018078392A1 (en) Polymorphs of dasatinib
WO2013132511A1 (en) Novel polymorph of lurasidone hydrochloride
EA025561B1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
JP7295025B2 (ja) （ｓ）－［２－クロロ－４－フルオロ－５－（７－モルホリン－４－イルキナゾリン－４－イル）フェニル］－（６－メトキシ－ピリダジン－３－イル）メタノールの結晶性形態
CN111484489B (zh) 无定形的b-raf激酶二聚体抑制剂
CN111484488A (zh) 一种b-raf激酶二聚体抑制剂的稳定结晶形式a
HK1171750B (en) Novel forms of a multicyclic compound
KR20120123259A (ko) (4-히드록시카르바모일-페닐)-카르밤산 (6-디메틸아미노 메틸-2-나프탈에닐) 에스테르의 히드로클로라이드의 신규 다형체
JP2009513582A (ja) ４−オキソ−１−（３置換フェニル）−１，４−ジヒドロ−１，８−ナフチリジン−３−カルボキサミドホスホジエステラーゼ４阻害剤及びその製造方法
WO2010131118A2 (en) Polymorphs of etravirine and processes for preparation thereof
MX2011005055A (es) Nuevas formas de un compuesto de indazolo [5,4-a]pirrolo[3,4-c]car bazol.
AU2018201013B2 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
ES2316270B1 (es) Nueva forma cristalina de moxifloxacino clorhidrato anhidro forma iv .
CN119859139A (zh) 双盐酸安罗替尼的固体形式及其制备方法
EA047214B1 (ru) СТАБИЛЬНЫЕ ТВЕРДЫЕ ДИСПЕРСИИ ИНГИБИТОРА ДИМЕРА КИНАЗЫ B-Raf, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЯ
JP2003300974A (ja) ファシドトリルの多形型と、その製造方法およびそれを含む医薬組成物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired